GlassScriptPhysician profile
Tekisha Rina Freeman
NPI 1861035289
$2,006.20
in general payments reported to CMS, 2019-2025
33 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,441 · 2022: $124 · 2023: $233 · 2024: $79.09 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $440.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $276.64 | 2021-2025 | |
| Novo Nordisk INC | $191.46 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $190.34 | 2021-2024 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $101.78 | 2021-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $97.80 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $92.35 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.42 | 2023-2025 | |
| Esperion Therapeutics, INC. | $85.52 | 2021 | |
| Paratek Pharmaceuticals, INC. | $83.52 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $67.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.38 | 2021 | |
| Glaxosmithkline, LLC. | $59.47 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $52.68 | 2021 | |
| Mylan Specialty L.P. | $50.25 | 2021 | |
| Lilly USA, LLC | $45.09 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $45.05 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.71 | 2021 | |
| Exact Sciences Corporation | $39.71 | 2024-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $35.70 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.35 | 2021 | |
| Horizon Therapeutics Plc | $30.76 | 2021 | |
| Ironwood Pharmaceuticals, INC | $30.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.59 | 2021-2023 | Xarelto |
| Eisai INC. | $25.21 | 2021-2022 | |
| Dexcom, INC. | $24.82 | 2025 | Dexcom G6 Transmitter |
| Masimo Corporation | $24.12 | 2021 | |
| Forte Bio-Pharma LLC | $18.92 | 2021 | |
| Pfizer INC. | $15.30 | 2021 | |
| Corcept Therapeutics | $13.75 | 2023 | Korlym |
| Dynavax Technologies Corporation | $13.11 | 2024 | Heplisav-B |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.02 | 2022 | |
| Allergan, INC. | $12.20 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tekisha Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.